BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:11 PM
 | 
Jun 21, 2007
 |  BC Extra  |  Company News

Genzyme, Ceregene in gene therapy deal

Ceregene (San Diego, Calif.) granted GENZ exclusive rights outside the U.S. and Canada to CERE-120 to treat Parkinson's disease. The adeno-associated viral (AAV) Type 2 vector encoding the neurturin...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >